Last reviewed · How we verify
NCT06772298: SALT
Study of Oxidized Albumin in Liver Transplant Patients
trial in Liver Failure in 10 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Region Stockholm |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 1 February 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2026 |
Conditions studied
- Liver Failure — all drugs for Liver Failure →
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
- Liver Transplant Disorder — all drugs for Liver Transplant Disorder →
Sponsor
Region Stockholm — full company profile →
Who can join
18 and older, any sex, with Liver Failure or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal is to describe the oxidation state of albumin before, during and after liver transplantation. This is a pilot observational study in which the oxidative state in 10 patients undergoing liver transplantation will be described. Samples for analysing the oxidation state of albumin, general oxidative damage and anti-oxidant state, the activation of the complement system and factors involved in coagulation will be obtained before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06772298
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Failure
Currently open trials in the same condition.
- NCT07312864 — Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome · Phase 1, PHASE2 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
- NCT06908746 — Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A · recruiting
- NCT06224023 — Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure · recruiting
Other Region Stockholm trials
Trials by the same sponsor.
- NCT06304363 — Braining - Evaluation of Acute Effects of Physical Exercise · NA · not yet recruiting
- NCT07089771 — Virtual Versus Dye-based Chromoendoscopy in Inflammatory Bowel Disease Surveillance Colonoscopy · NA · not yet recruiting
- NCT07503951 — Cognitive Behavior Therapy in Psychiatric Inpatient Care · NA · not yet recruiting
- NCT07434219 — A Group Based Psychoeducational Intervention for Partners of Child Sexual Abuse Material Offenders. · NA · not yet recruiting
- NCT07464730 — Postoperative High-flow Nasal Oxygenation After High-risk Surgery in the Frail Adult · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06772298 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Stockholm
- Last refreshed: 13 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06772298.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing